Sirolimus and Everolimus Induce Endothelial Cellular Senescence Via Sirtuin 1 Down-Regulation

Objectives The aim of this study was to compare the effects of paclitaxel, sirolimus, and everolimus on the senescent phenotype in human endothelial cells, and to further investigate possible involvement of mammalian sirtuin 1 (Sirt1) down-regulation as a mechanism. Background Endothelial cell senescence may play a role in impaired re-endothelialization after drug-eluting stent (DES) implantation. Recently, the down-regulation of Sirt1 has been shown to mediate oxidative stress-induced endothelial senescence. Methods Senescent human umbilical vein endothelial cells (HUVEC) were judged by senescence-associated beta-galactosidase assay (SA-beta gal), morphological appearance, and plasminogen activator inhibitor (PAI)-1. Results Treatment with paclitaxel, sirolimus, and everolimus significantly caused a senescent phenotype and PAI-1 upregulation, associated with a decrease in endothelial nitric oxide synthase (eNOS) and Sirt1 expression. Overexpression of Sirt1 or Sirt1 activation reversed the sirolimus-or everolimus-induced senescent phenotype. Interestingly, paclitaxel-induced senescence was not suppressed by Sirt1 overexpression, suggesting the existence of a different mechanism. Cilostazol markedly inhibited the sirolimus-or everolimus-induced senescent phenotype (sirolimus or everolimus [2.5 nmol/l]; 49.2% or 53.0% SA-beta gal positive vs. only 13.6% or 14.6% with cilostazol [100 mu mol/l]) and PAI-1 up-regulation, but had no influence on the effects of paclitaxel. Finally, aspirin significantly blunted sirolimus-or everolimus-induced senescence, but neither ticlopidine nor clopidogrel had any effects. Conclusions Sirolimus and everolimus induce endothelial senescence involving down-regulation of Sirt1. In contrast, the development of endothelial senescence by paclitaxel involves a Sirt1-independent pathway. Because sirolimus and everolimus are involved in Sirt1 modulation, cilostazol rescues HUVEC from sirolimus-or everolimus-induced senescence. These results may have therapeutic implications in the clinical sequelae after DES implantation. (J Am Coll Cardiol 2009; 53: 2298-305) (C) 2009 by the American College of Cardiology Foundation